Repositioning a JAKi to Reduce Mortality in Patients with COVID-19
Time: 11:45 am
day: Day One
Details:
- Rationalizing the use of a JAKi in COVID-19 patients
- Reviewing the data from a phase 3 COVID-19 trial
- Exploring other potential novel therapeutic targets for Baricitinib
